Senior insider sale
SPYRE THERAPEUTICS, INC. — senior position signals high conviction
$399.66M
4.68M shares
FAIRMOUNT FUNDS MANAGEMENT LLC plans to sell 4.68M shares of SPYRE THERAPEUTICS, INC. valued at approximately $399.66M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Conversion of Series B Non-Voting Convertible Preferred Stock
Conversion of Series B Non-Voting Convertible Preferred Stock into Common Stock
Exchange of Series A Non-Voting Convertible Preferred Stock
Exchange of Series A Non-Voting Convertible Preferred Stock into Common Stock
Acquired in reverse merger transaction
Acquired in reverse merger transaction
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
6/23/2026 | Conversion of Series B Non-Voting Convertible Preferred Stock Conversion of Series B Non-Voting Convertible Preferred Stock into Common Stock | 666.68K | — |
4/25/2024 | Exchange of Series A Non-Voting Convertible Preferred Stock Exchange of Series A Non-Voting Convertible Preferred Stock into Common Stock | 3.64M | — |
6/22/2023 | Acquired in reverse merger transaction Acquired in reverse merger transaction | 378.42K | — |
| Total | 4.68M | ||
Units to sell
4.68M
Market value
$399.66M
Units
4.68M
Value
$399.66M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
6/23/2026 | 4.68M | $399.66M | NASDAQ | Planned |
| Total | 4.68M | $399.66M | ||